{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T06:42:37Z","timestamp":1768718557616,"version":"3.49.0"},"reference-count":30,"publisher":"Danish Medical Association","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ugeskr L\u00e6ger"],"abstract":"<jats:p>Current guidelines recommend screening with serum M-protein and serum-free light chain analysis (S-FLC) when an M-protein-related disorder is suspected. Many patients with multiple myeloma will be overlooked if only serum M-protein is measured. Despite this, the general practitioners in some areas of Denmark cannot order S-FLC. This review aims to disseminate knowledge of the S-FLC analysis, its applicability, and limitations in the diagnostic workup for suspected monoclonal gammopathies.<\/jats:p>","DOI":"10.61409\/v12230766","type":"journal-article","created":{"date-parts":[[2024,8,2]],"date-time":"2024-08-02T12:35:48Z","timestamp":1722602148000},"page":"1-6","source":"Crossref","is-referenced-by-count":1,"title":["Serum-free light chains in the evaluation of M-component disease"],"prefix":"10.61409","author":[{"given":"Stine","family":"Rasch","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charlotte Toftmann","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Niels","family":"Abilgaard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"40208","published-online":{"date-parts":[[2024,7,15]]},"reference":[{"issue":"5","key":"ref0","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1046\/j.1365-2141.2003.04355.x","article-title":"Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group","volume":"121","author":"Myeloma Working Group","year":"2003","unstructured":"International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol. 2003;121(5):749-57.","journal-title":"Br J Haematol"},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"Derman B, Castillo JJ, Sarosiek S, Beksac M. When a monoclonal gammopathy is not multiple myeloma. Am Soc Clin Oncol Educ Book. 2022;42:1-10. https:\/\/doi.org\/10.1200\/EDBK_349643","DOI":"10.1200\/EDBK_349643"},{"key":"ref2","unstructured":"Danske Multidisciplin\u00e6re Cancer Grupper, Regionernes Kliniske Kvalitetsudviklingsprogram (RKKP). Diagnostik og opf\u00f8lgning af myelomatose, 2023. https:\/\/www.dmcg.dk\/Kliniske-retningslinjer\/kliniske-retningslinjer-opdelt-paa-dmcg\/myelomatose\/diagnostik-og-opfolgning-af-myelomatose\/ (17. juni 2024)."},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"McTaggart MP, Lindsay J, Kearney EM. Replacing urine protein electrophoresis with serum free light chain analysis as a first-line test for detecting plasma cell disorders offers increased diagnostic accuracy and potential health benefit to patients. Am J Clin Pathol. 2013;140(6):890-7. https:\/\/doi.org\/10.1309\/AJCP25IHYLEWCAHJ","DOI":"10.1309\/AJCP25IHYLEWCAHJ"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"Sarto C, Intra J, Fania C et al. Monoclonal free light chain detection and quantification: performances and limits of available laboratory assays. Clin Biochem. 2021;95:28-33. https:\/\/doi.org\/10.1016\/j.clinbiochem.2021.05.006","DOI":"10.1016\/j.clinbiochem.2021.05.006"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"Dispenzieri A, Kyle R, Merlini G et al. International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia. 2009;23(2):215-24. https:\/\/doi.org\/10.1038\/leu.2008.307","DOI":"10.1038\/leu.2008.307"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"Hill PG, Forsyth JM, Rai B et al. Serum free light chains: an alternative to the urine Bence Jones proteins screening test for monoclonal gammopathies. Clin Chem. 2006;52(9):1743-8. https:\/\/doi.org\/10.1373\/clinchem.2006.069104","DOI":"10.1373\/clinchem.2006.069104"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"Sandfeld-Paulsen B, Aggerholm-Pedersen N, Samson MH, M\u00f8ller HJ. A cohort study of free light chain ratio in combination with serum protein electrophoresis as a first-line test in general practice. Cancers (Basel). 2022;14(12):2930. https:\/\/doi.org\/10.3390\/cancers14122930","DOI":"10.3390\/cancers14122930"},{"issue":"4","key":"ref8","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1093\/clinchem\/47.4.673","article-title":"Highly sensitive, automated immunoassay for immunoglobulin free light chains in serum and urine","volume":"47","author":"Bradwell","year":"2001","unstructured":"Bradwell AR, Carr-Smith HD, Mead GP et al. Highly sensitive, automated immunoassay for immunoglobulin free light chains in serum and urine. Clin Chem. 2001;47(4):673-80.","journal-title":"Clin Chem"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"Drayson M, Tang LX, Drew R et al. Serum free light-chain measurements for identifying and monitoring patients with nonsecretory multiple myeloma. Blood 2001;97:2900-2. https:\/\/doi.org\/10.1182\/blood.v97.9.2900","DOI":"10.1182\/blood.V97.9.2900"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"Bradwell AR, Carr-Smith HD, Mead GP et al. Serum test for assessment of patients with Bence Jones myeloma. Lancet. 2003;361(9356):489-91. https:\/\/doi.org\/10.1016\/S0140-6736(03)12457-9","DOI":"10.1016\/S0140-6736(03)12457-9"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"Katzmann JA, Dispenzieri A, Kyle RA et al. Elimination of the need for urine studies in the screening algorithm for monoclonal gammopathies by using serum immunofixation and free light chain assays. Mayo Clin Proc. 2006;81(12):1575-8. https:\/\/doi.org\/10.4065\/81.12.1575","DOI":"10.4065\/81.12.1575"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"Vermeersch P, Van Hoovels L, Delforge M et al. Diagnostic performance of serum free light chain measurement in patients suspected of a monoclonal B-cell disorder. Br J Haematol. 2008;143(4):496-502. https:\/\/doi.org\/10.1111\/j.1365-2141.2008.07369.x","DOI":"10.1111\/j.1365-2141.2008.07369.x"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"Rajkumar SV, Dimopoulos MA, Palumbo A et al. International myeloma working group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014. 15(12):e538-48. https:\/\/doi.org\/10.1016\/S1470-2045(14)70442-5","DOI":"10.1016\/S1470-2045(14)70442-5"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"Kumar S, Paiva B, Anderson KC et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17(8):e328-e346. https:\/\/doi.org\/10.1016\/S1470-2045(16)30206-6","DOI":"10.1016\/S1470-2045(16)30206-6"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"Mateos M-V, Kumar S, Dimopoulos MA et al. International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM). Blood Cancer J. 2020;10(10):102. https:\/\/doi.org\/10.1038\/s41408-020-00366-3","DOI":"10.1038\/s41408-020-00366-3"},{"key":"ref16","unstructured":"Abildgaard N. M-komponentsygdomme, 2024. Ugeskr L\u00e6ger. 2021;183:V03210258."},{"key":"ref17","unstructured":"Danske Multidisciplin\u00e6re Cancer Grupper. M-komponent analyser ved myelomatose, version 1.1, 2022. https:\/\/www.dmcg.dk\/Kliniske-retningslinjer\/kliniske-retningslinjer-opdelt-paa-dmcg\/myelomatose\/m-komponent-analyser-ved-myelomatose\/ (17. juni 2024)."},{"key":"ref18","unstructured":"Spanggaard MBL, Hansen CT, Michael Maiborg et al. Amyloidose er en sygdom med mange ansigter. Ugeskr L\u00e6ger. 2023;185:V08220479."},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"Caponi L, Romiti N, Koni E et al. Inter-assay variability in automated serum free light chain assays and their use in the clinical laboratory. Crit Rev Clin Lab Sci. 2020;57(2):73-85. https:\/\/doi.org\/10.1080\/10408363.2019.1670133","DOI":"10.1080\/10408363.2019.1670133"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"Long TE, Indridason OS, Palsson R et al. Defining new reference intervals for serum free light chains in individuals with chronic kidney disease: results of the iStopMM study. Blood Cancer J. 2022;12(9):133. https:\/\/doi.org\/10.1038\/s41408-022-00732-3","DOI":"10.1038\/s41408-022-00732-3"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"Molina-And\u00fajar A, Robles P, Cibeira MT et al. The renal range of the \u03ba\/\u03bb sFLC ratio: best strategy to evaluate multiple myeloma in patients with chronic kidney disease. BMC Nephrol. 2020;21(1):111. https:\/\/doi.org\/10.1186\/s12882-020-01771-3","DOI":"10.1186\/s12882-020-01771-3"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"Singh G. Serum free light chain assay and \u03ba\/\u03bb ratio performance in patients without monoclonal gammopathies high false-positive rate. Am J Clin Pathol. 2016;146(2):207-14. https:\/\/doi.org\/10.1093\/ajcp\/aqw099","DOI":"10.1093\/ajcp\/aqw099"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"Xu L, Zhao B, Sun Y et al. Using two detection methods to observe the changes and significance of free light chain in serum and urine in patients with renal insufficiency. Biomed Res Int. 2022;2022:5536199. https:\/\/doi.org\/10.1155\/2022\/5536199","DOI":"10.1155\/2022\/5536199"},{"issue":"2","key":"ref24","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1093\/clinchem\/48.9.1437","article-title":"Serum reference intervals and diagnostic ranges for free \u03ba and free \u03bb immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains","volume":"48","author":"Katzmann","year":"2002","unstructured":"Katzmann JA, Clark RJ, Abraham RS et al. Serum reference intervals and diagnostic ranges for free \u03ba and free \u03bb immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains. Clin Chem. 2002;48(2):1437-44.","journal-title":"Clin Chem"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"Azimi V, Slade M, Fiala M et al. A single reference interval for interpreting serum free light chains across patients with varying renal function. Clin Chem. 2023;hvad043. https:\/\/doi.org\/10.1093\/clinchem\/hvad043","DOI":"10.1093\/clinchem\/hvad043"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"Murray D, Dispenzieri A, Kumar S et al. Free light chain assay drift: potential for misdiagnosis? J Appl Lab Med. 2020;5(6):1411-3. https:\/\/doi.org\/10.1093\/10.1093\/jalm\/jfaa093","DOI":"10.1093\/jalm\/jfaa093"},{"key":"ref27","doi-asserted-by":"publisher","unstructured":"Rozenova K, Willrich M, Snyder M et al. Kappa free light chain drift prompts the need for a new upper limit of normal free light chain ratio to avoid an epidemic of kappa light chain monoclonal gammopathy of undermined significance. J Appl Lab Med. 2023;8(4):742-750. https:\/\/doi.org\/10.1093\/jalm\/jfad027","DOI":"10.1093\/jalm\/jfad027"},{"key":"ref28","doi-asserted-by":"publisher","unstructured":"Gudowska-Sawczuk M, Mroczko B. Free light chains \u03ba and \u03bb as new biomarkers of selected diseases. Int J Mol Sci. 2023;24(11):9531. https:\/\/doi.org\/10.3390\/ijms24119531","DOI":"10.3390\/ijms24119531"},{"key":"ref29","doi-asserted-by":"publisher","unstructured":"Brebner JA, Stockley RA. Polyclonal free light chains: a biomarker of inflammatory disease or treatment target? F1000 Med Rep. 2013;5:4. https:\/\/doi.org\/10.3410\/M5-4","DOI":"10.3410\/M5-4"}],"container-title":["Ugeskrift for L\u00e6ger"],"original-title":[],"deposited":{"date-parts":[[2024,8,13]],"date-time":"2024-08-13T08:36:43Z","timestamp":1723538203000},"score":1,"resource":{"primary":{"URL":"https:\/\/ugeskriftet.dk\/videnskab\/V12230766"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,15]]},"references-count":30,"URL":"https:\/\/doi.org\/10.61409\/v12230766","relation":{},"ISSN":["0041-5782","1603-6824"],"issn-type":[{"value":"0041-5782","type":"print"},{"value":"1603-6824","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,15]]}}}